Therefore, in the present study, we evaluated the impact of CD3+, CD68+, and PD-L1 expression on MKI responses and patient outcomes, investigating tissue samples from patients with unresectable HCC via immunohistochemistry. The gene discussed is CD274; the disease is hepatocellular carcinoma.